Cover Image
市場調查報告書

臍帶血幹細胞的全球市場:2015年∼2019年

Global Stem Cell Umbilical Cord Blood Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 337795
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
臍帶血幹細胞的全球市場:2015年∼2019年 Global Stem Cell Umbilical Cord Blood Market 2015-2019
出版日期: 2015年08月19日 內容資訊: 英文 79 Pages
簡介

全球臍帶血 (UCB) 幹細胞市場預測在2014年∼2019年間將以年複合成長率(CAGR)30.36%的速度成長。

本報告提供全球臍帶血幹細胞市場相關調查分析,提供您市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 臍帶血 (UCB) 細胞的採取·處理·保管的流程

  • 捐贈者評估
  • 採取方法
  • 處理·保管方法
  • 樣品保持·保管期間

第7章 fact:臍帶血

第8章 美國的FDA核凖的臍帶血幹細胞產品

  • Hemacord

第9章 開發平台分析

  • 開發平台候補相關資訊

第10章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第11章 市場區隔:各應用

  • 癌症
  • 血液疾病
  • 代謝疾病
  • 免疫疾病
  • 其他

第12章 市場區隔:保管別

  • 公共銀行
  • 私人銀行
  • 官民銀行

第13章 生物銀行的協調

第14章 市場區隔:各終端用戶

  • 研究機關
  • 製藥公司
  • 生物銀行
  • 醫院

第15章 地理區分

  • 南北美洲
  • 歐洲·中東·非洲
  • 亞太地區

第16章 購買標準

第17章 推動市場成長要素

第18章 成長推動因素與其影響

第19章 市場課題

第20章 成長推動因素與課題的影響

第21章 市場趨勢

第22章 趨勢與其影響

第23章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他·有未來潛力的供應商

第24章 全球臍帶血幹細胞市場:要點

第25章 主要供應商分析

  • Caladrious
  • Celgene
  • Mesoblast
  • Pluristem

第26章 相關報告

圖表

目錄
Product Code: IRTNTR6649

About Stem Cell UCB

UCB is the blood that remains in the placenta and the attached umbilical cord after childbirth. UCB contains stem cells that are unique, smart, and are capable of treating several life-threatening diseases. They are used in the treatment of hematopoietic and genetic disorders. The placental blood can produce 10 times more quantity of stem cells compared to the umbilical cord, which can in turn be used for the treatment of an adult patient. The cord blood that is collected during the childbirth is stored and cryopreserved. The storage of the cord blood can be done at private cord blood banks or public cord blood banks. This preserved blood can be used for the transplantation, and treatment of diseases at the later stages of life.

Technavio's analysts forecast the global stem cell UCB market to grow at a CAGR of 30.36% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global stem cell UCB market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the banking and utilization of UCB stem cells for the treatment of various disorders, such as cancers, blood disorders, metabolic disorders, immune diseases, and others.

Technavio's report, Global Stem Cell UCB Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global stem cell UCB market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Caladrius Biosciences
  • Celgene
  • Mesoblast
  • Pluristem Therapeutics

Other Prominent Vendors

  • Athersys
  • CHA Bio & Diostech
  • Cytori Therapeutics
  • Nuo Therapeutics
  • Ocata Therapeutics
  • Opexa Therapeutics
  • Osiris Therapeutics
  • Teva Pharmaceuticals
  • United Therapeutics

Key Market Driver

  • Effective Treatment of Life-threatening Diseases
  • For a full, detailed list, view our report

Key Market Challenge

  • Stringent Regulations
  • For a full, detailed list, view our report

Key Market Trend

  • Growing Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Process of Collection, Processing, and Storage of Cord Blood Cells

  • 06.1. Donor Evaluation
  • 06.2. Collection Methods
  • 06.3. Processing and Storage Methods
  • 06.4. Sample Retention and Length of Storage

07. Facts: Cord Blood Units

08. US FDA Approved Stem Cell UCB Product

  • 08.1. Hemacord
    • 08.1.1. Mechanism of Action
    • 08.1.2. Side Effects

09. Pipeline Analysis

  • 09.1. Information on Pipeline Candidates
    • 09.1.1. PDA-002
    • 09.1.2. PDA-001
    • 09.1.3. PLX-PAD
    • 09.1.4. PLX-R18

10. Market Landscape

  • 10.1. Market Overview
  • 10.2. Market Size and Forecast
  • 10.3. Five Forces Analysis

11. Market Segmentation by Application

  • 11.1. Cancers
  • 11.2. Blood Disorders
  • 11.3. Metabolic Disorders
  • 11.4. Immune Disorders
  • 11.5. Others

12. Market Segmentation by Storage

  • 12.1. Public Cord Blood Bank
  • 12.2. Private Cord Blood Bank
  • 12.3. Public-Private Cord Blood Banks

13. Harmonization of Biobanking

14. Market Segmentation by End-user

  • 14.1. Research Institutes
  • 14.2. Pharmaceutical Companies
  • 14.3. Biobanks
  • 14.4. Hospitals

15. Geographical Segmentation

  • 15.1. Stem Cell UCB Market in Americas
    • 15.1.1. Market Size and Forecast
  • 15.2. Stem Cell UCB Market in EMEA
    • 15.2.1. Market Size and Forecast
  • 15.3. Stem Cell UCB Market in APAC
    • 15.3.1. Market Size and Forecast

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and their Impact

23. Vendor Landscape

  • 23.1. Competitive Scenario
    • 23.1.1. Key News
    • 23.1.2. Mergers and Acquisitions
  • 23.2. Market Share Analysis 2014
    • 23.2.1. Caladrius Biosciences
    • 23.2.2. Celgene Corp.
    • 23.2.3. Mesoblast Ltd.
    • 23.2.4. Pluristem Therapeutics
  • 23.3. Other and Future Prominent Vendors

24. Global Stem Cell UCB Market: Key Takeaways

25. Key Vendor Analysis

  • 25.1. Caladrious
    • 25.1.1. Key Facts
    • 25.1.2. Business Overview
    • 25.1.3. Business Segmentation by Revenue 2014
    • 25.1.4. Business Segmentation by Revenue 2013 and 2014
    • 25.1.5. Geographical Segmentation by Revenue 2014
    • 25.1.6. Business Strategy
    • 25.1.7. Recent Developments
    • 25.1.8. SWOT Analysis
  • 25.2. Celgene
    • 25.2.1. Key Facts
    • 25.2.2. Business Overview
    • 25.2.3. Business Strategy
    • 25.2.4. Business Segmentation by Revenue
    • 25.2.5. Sales by Geography
    • 25.2.6. Key Information
    • 25.2.7. SWOT Analysis
  • 25.3. Mesoblast
    • 25.3.1. Key Facts
    • 25.3.2. Business Overview
    • 25.3.3. Therapeutic Areas
    • 25.3.4. Geographical Segmentation
    • 25.3.5. Business Strategy
    • 25.3.6. Recent Developments
    • 25.3.7. SWOT Analysis
  • 25.4. Pluristem
    • 25.4.1. Key Facts
    • 25.4.2. Business Overview
    • 25.4.3. Geographical Presence
    • 25.4.4. Business Strategy
    • 25.4.5. Recent Developments
    • 25.4.6. SWOT Analysis

26. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Donor Evaluation before Collection of Cord Blood Cells
  • Exhibit 3: Collection of Cord Blood Cells
  • Exhibit 4: Processing and Storage Methods of Cord Blood Cells
  • Exhibit 5: Stem Cell Transplantations by Patient Race in US
  • Exhibit 6: Pipeline Portfolio of Stem Cell UCB Products for Different Diseases
  • Exhibit 7: Global Stem Cell UCB Market 2014-2019 ($ millions)
  • Exhibit 8: Global Stem Cell UCB Market Segment by Application
  • Exhibit 9: Global Stem Cell UCB Market Segmentation by Storage
  • Exhibit 10: Organizations and Initiatives Toward Biobank Harmonization
  • Exhibit 11: Key Factors Involved in Harmonization of Biobanks
  • Exhibit 12: Key Focus Areas in Harmonization of Biobanks
  • Exhibit 13: Organizations and Initiatives in Harmonizing Science and Infrastructure
  • Exhibit 14: Initiatives on Biobanking Resource Tools and Databases
  • Exhibit 15: Global Stem Cell UCB Market Segment by End-user
  • Exhibit 16: Segmentation of Global Stem Cell UCB Market by Geography 2014
  • Exhibit 17: Stem Cell UCB Market in Americas 2014-2019 ($ millions)
  • Exhibit 18: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
  • Exhibit 19: Stem Cell UCB Market in APAC 2014-2019 ($ millions)
  • Exhibit 20: Statistics of Stem Cell UCB Market by Geography
  • Exhibit 21: Global Stem Cell UCB Market: Key Takeaways
  • Exhibit 22: Caladrious: Business Segmentation by Revenue 2014
  • Exhibit 23: Caladrious: Business Segmentation by Revenue 2013 and 2014 ($ millions)
  • Exhibit 24: Caladrious: Geographical Segmentation by Revenue 2014
  • Exhibit 25: Celgene: Business Segmentation by Revenue 2011-2013 ($ millions)
  • Exhibit 26: Celgene: Sales by Geography 2013
  • Exhibit 27: Mesoblast: Therapeutic Areas
  • Exhibit 28: Mesoblast: Geographical Segmentation
  • Exhibit 29: PLuristem: Geographical Presence
Back to Top